1-8 of 8
Robert A. Beckman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Agnostic Approvals: Insights and Practical Considerations

Available to Purchase
Chengxing Cindy Lu, Robert A. Beckman, Xiaoyun Nicole Li, Weidong Zhang, Qi Jiang, Olga Marchenko, Zhiping Sun, Hong Tian, Jingjing Ye, Shuai Sammy Yuan, Godwin Yung, on behalf of the Master Protocol subteam of the Statistical Methods in Oncology Scientific Working Group, Biopharmaceutical Session, American Statistical Association
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 480–488.
https://doi.org/10.1158/1078-0432.CCR-23-1340
Published: 01 February 2024
View articletitled, Tumor-Agnostic Approvals: Insights and Practical Considerations
Open the PDF for Tumor-Agnostic Approvals: Insights and Practical Considerations in another window
Journal Articles

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Free
Magnus T. Dillon, Lorna Grove, Kate L. Newbold, Heather Shaw, Nicholas F. Brown, Jeanne Mendell, Shuquan Chen, Robert A. Beckman, Anne Jennings, Marivic Ricamara, Jonathan Greenberg, Martin Forster, Kevin J. Harrington
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (2): 487–495.
https://doi.org/10.1158/1078-0432.CCR-18-1539
Published: 15 January 2019
View articletitled, Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Open the PDF for Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Free
Timothy A. Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Ivy Fearen, Kyriakos P. Papadopoulos, David Olmos, Richard Baird, Liliana Delgado, Ernestina Tetteh, Robert A. Beckman, Lisa Lupinacci, Ruth Riisnaes, Shaun Decordova, Simon P. Heaton, Karen Swales, Nandita M. deSouza, Martin O. Leach, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5672–5685.
https://doi.org/10.1158/1078-0432.CCR-14-0868
Published: 13 November 2014
View articletitled, Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Open the PDF for Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers in another window
Includes: Supplementary data
Journal Articles

Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials

Free
Cong Chen, Robert A. Beckman
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1730–1734.
https://doi.org/10.1158/1078-0432.CCR-13-2312
Published: 31 March 2014
View articletitled, Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials
Open the PDF for Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials in another window
Journal Articles

Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008

Free
Ingrid J.G. Burvenich, Fook T. Lee, Glenn A. Cartwright, Graeme J. O'Keefe, Dahna Makris, Diana Cao, Sylvia Gong, Anderly C. Chueh, John M. Mariadason, Martin W. Brechbiel, Robert A. Beckman, Kosaku Fujiwara, Reinhard von Roemeling, Andrew M. Scott
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (21): 5984–5993.
https://doi.org/10.1158/1078-0432.CCR-12-3104
Published: 31 October 2013
View articletitled, Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008
Open the PDF for Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008 in another window
Includes: Supplementary data
Journal Articles

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Free
Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira, Naiyer Rizvi, Lisa Malburg, Vicki Keedy, Lorrin Yee, Catherine Copigneaux, Thore Hettmann, Chi-Yuan Wu, Agnes Ang, Abdel-Baset Halim, Robert A. Beckman, Darrin Beaupre, Jordan Berlin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3078–3087.
https://doi.org/10.1158/1078-0432.CCR-12-3051
Published: 30 May 2013
View articletitled, Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

Free
Francesco Atzori, Josep Tabernero, Andrés Cervantes, Ludmila Prudkin, Jordi Andreu, Edith Rodríguez-Braun, Amparo Domingo, Jorge Guijarro, Cristina Gamez, Jordi Rodon, Serena Di Cosimo, Holly Brown, Jason Clark, James S. Hardwick, Robert A. Beckman, William D. Hanley, Karl Hsu, Emiliano Calvo, Susana Roselló, Ronald B. Langdon, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (19): 6304–6312.
https://doi.org/10.1158/1078-0432.CCR-10-3336
Published: 02 October 2011
View articletitled, A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

Free
Saifee A. Mullamitha, Nhuan C. Ton, Geoff J.M. Parker, Alan Jackson, Peter J. Julyan, Caleb Roberts, Gio A. Buonaccorsi, Yvonne Watson, Karen Davies, Sue Cheung, Lynn Hope, Juan W. Valle, John A. Radford, Jeremy Lawrance, Mark P. Saunders, Mihaela C. Munteanu, Marian T. Nakada, Jeffrey A. Nemeth, Hugh M. Davis, Qun Jiao, Uma Prabhakar, Zhihui Lang, Robert E. Corringham, Robert A. Beckman, Gordon C. Jayson, in association with the Biotherapy Development Association
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2128–2135.
https://doi.org/10.1158/1078-0432.CCR-06-2779
Published: 02 April 2007
View articletitled, Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors in another window